News and Trends 7 Jan 2019 Sanofi Invests €80M in mRNA Cancer Vaccine Company Sanofi is to make an €80M equity investment in the German biotech BioNTech, and the two have agreed to co-develop a cancer vaccine based on injecting messenger RNA into solid tumors. This agreement is an extension of Sanofi and BioNTech’s collaboration, which began in 2015. The two companies will continue to co-develop and co-commercialize a candidate […] January 7, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2018 Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials A European trial has proved the feasibility and efficacy of treating cancer with a personalized immunotherapy tailored to each patient. The phase I/II trial, run across six European centers, tested a combination of two personalized vaccines in patients with glioblastoma, an aggressive form of brain cancer. The first vaccine was designed to immunize the patients […] December 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2018 What Does the Largest Biotech IPO Ever Mean for European Biotech? With a massive €530M ($604M) raised, US-based Moderna has made a record biotech IPO. The news could give a significant boost to developers of messenger RNA, a technology that is still several years away from the market. Entering the Nasdaq with a €7B ($8B) market cap, Moderna made history last Friday with a technology that […] December 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 1 Oct 2018 Could These Innovative Flu Vaccines Prevent Deaths From Deadly Outbreaks? Despite more than a century of scientific endeavour, influenza remains one of the most deadly infectious diseases worldwide. Across Europe, many biotechs are working on novel solutions that could dramatically improve the protection rates offered by current vaccines. Some may even lead to the holy grail of influenza research – a universal flu vaccine. Each […] October 1, 2018 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2018 Pfizer Offers €374M for German mRNA Flu Vaccine BioNTech, based in Mainz, Germany, has entered into a partnership with Pfizer worth up to $425M (€374M) to develop an mRNA-based flu vaccine, which could be produced much more quickly than current flu vaccines. Messenger RNA (mRNA) is one of the building blocks living organisms use to create proteins from genes. BioNTech is developing prophylactic […] August 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2018 Money, Money, Money! Europe’s Best-Funded Biotechs in 2018 Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on the brain, we thought it would be a good time to do a roundup of Europe’s best-funded private biotechs. With over €400M raised to date, […] February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Scancell and BioNTech Will Combine Their Expertise to Fight Cancer Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer cells, opening the door to new cancer treatments that target them. Scancell works on immunotherapies for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 German Biotech Raises Record $270M Series A for Individualized Cancer Therapies BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and mRNA technologies. BioNTech is kicking off the new year with great news. The company has closed its Series A with $270M (€225M) — a record amount in Germany for such an early funding round. The fundraising was led by the […] January 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine Moderna Therapeutics has started dosing patients with an mRNA-based personalized cancer vaccine that resembles another one being developed by BioNTech. Moderna Therapeutics has announced the start of a Phase 1 study with mRNA-4157, a therapy consisting of a cancer vaccine that is tailored to each patient’s individual tumor. In order to make this personalized treatment, […] November 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 German Biotech Teams Up with BioNTech to Boost Antibody Development MAB Discovery and BioNTech are working together to push through the development of new antibody therapeutics using MAB’s technology platform. MAB Discovery creates monoclonal antibodies by stimulating natural antibody maturation using its own sophisticated platform. On the back of a highly productive agreement signed in 2013, BioNTech, Europe’s largest privately held biopharma, has moved to agree […] November 6, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 9 Oct 2017 The Woman Developing the Next Generation of Cancer Immunotherapy Özlem Türeci discusses the future of individualized cancer therapy and her journey to become an entrepreneur and take science to patients. As a trained physician and immunologist, Dr. Özlem Türeci has led her own research group with Prof. Ugur Sahin at the University of Mainz, Germany, since 2000. But academic research was not enough for her, […] October 9, 2017 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Sep 2017 These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare Biotech is the best source of innovation in R&D, making its companies the darlings of pharma. Which therapeutic fields belong to biotech? “Biotech is typically first in highly innovative fields,” Matt Kapusta, CEO of uniQure told us. Before he became CEO, uniQure brought the world’s first gene therapy to market — completely on its own. Biotech […] September 26, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email